DDIT3 and ocular hypertension: Identified molecules should then be carefully tested in a model of optic nerve injury or preferably, a model of ocular hypertension to determine 1) if these molecules are expressed at a time point consistent with glaucomatous injury 2) if manipulation of these molecules decreases JUN and DDIT3 expression and 3) if deficiency of these molecules protects RGC somas and their axons.